Preview

Вопросы гематологии/онкологии и иммунопатологии в педиатрии

Расширенный поиск

К вопросу о возможностях персонализации применения химиотерапии опухолей мозга на примере темозоломида

https://doi.org/10.24287/1726-1708-2017-16-2-84-90

Полный текст:

Аннотация

Широкое внедрение в протоколы лечения больных с опухолями ЦНС химиотерапии позволило улучшить прогноз для многих из них. В то же время у части больных использование адъювантной химиотерапии не дает желаемого эффекта, существенно повышает стоимость лечения, сопровождается токсическими осложнениями. На примере использования темозоломида (ТЗМ) в лечении глиом показано, что его применение позволяет улучшить результаты лечения только у части больных, имеющих комплекс положительных клинико-биологических и молекулярных характеристик. У остальных препарат не дает значимого эффекта и существенно повышает стоимость лечения. Опыт применения ТЗМ свидетельствует о возможности персонализации программы лечения на основании уже установленных факторов прогноза. Их использование позволит отказаться от стандартного применения химиопрепаратов по данным только патогистологической или только клинико-рентгенологической диагностики и руководствоваться индивидуализированными показаниями, основанными на имеющих прогностическое значение клинико-биологических параметрах и молекулярных характеристиках данной опухоли. Это позволит снизить стоимость лечения при сохранении его эффективности и уменьшении токсических осложнений.

Об авторах

О. И. Щербенко
ФГБУ «Российский научный центр рентгенорадиологии» Минздрава России, Москва
Россия


Э. В. Кумирова
ФГБУ «Национальный научно-практический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России, Москва
Россия


Список литературы

1. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2015 г. (заболеваемость и смертность). - М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России, 2017., илл., 250 с. http://www.oncology.ru/service/statistics/malignant_tumors/2015.pdf

2. Дяченко А.А., Субботина А.В., Измайлов Т.Р. и др. Эпидемиология первичных опухолей головного мозга (обзор литературы)//Вестник РНЦРР, 2013, вып. 13.

3. Plowman J., Waud W.R., Koutsoukos A.D., et al. Preclinical antitumor activity of temozolomide in mice: Efficacy against human brain tumors xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Canser Res 1994; 54 (14): 3793-9. [PubMed]

4. Newlands E.S., Blackledge G.R.P., Slack J.A., et al. Phase I trial of temozolomide (CCRG 81045: M&B 39381: NSC 362856). Br J Cancer 1992; 65 (1): 287-91. [PubMed]

5. Barone G., Maurizi P., Tamburrini G., Riccardi R. Role of temozolomide in pediatric brain tumors. Childs Nerv Syst 2006; 22 (7): 652-61. [PubMed]

6. Stupp R., Dietrich P.Y., Ostermann Kraljevic S., et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20 (5): 1375-82. [PubMed]

7. Koukourakis G.V., Kouloulias V., et al. Temozolomide with Radiation Therapy in High Grade Brain Gliomas: Pharmaceuticals Considerations and Efficacy; A Review Article. Molecules 2009; 14 (4): 561-77. [PubMed]

8. Feng E., Sui C., Wang T., Sun G. Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis. Eur Neurol 2017; 77 (3-4): 201-10. [PubMed]

9. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial). Lancet Oncol 2009; 10 (5): 459-66. [PubMed]

10. Esteller M., Garcia-Foncillas J., Andion E., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343 (19): 1350-4. [PubMed]

11. Hegi M.E., Diserens A.C., Godard S., et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10 (6): 1871-4. [PubMed]

12. Capdevila L., Cros S., Ramirez J.L., et al. Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation. J Neurooncol 2014; 117 (1): 77-84. [PubMed]

13. Minniti G., Scaringi C., Arcella A., et al. IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. J Neurooncol 2014; 118 (2): 377-83. [PubMed]

14. Bobola M.S., Alnoor M., Chen J.Y., et al. O6-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma. BBA Clin 2015; 3: 1-10. [PubMed]

15. Pollack I.F., Hamilton R.L., et al Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children’s Oncology Group. J Neurooncol 2010; 99 (1):155-63.

16. Thorarinsdottir H.K., Santi M., McCarter R., Rushing E.J., Cornelison R., Jales A., MacDonald T.J. Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas. Clin Cancer Res 2008; 14 (11): 3386-94.

17. Wu G., Broniscer A., et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 2012; 44 (3): 251-3.

18. Schiffman J.D., Hodgson J.G., et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 2010; 70 (2): 512-9.

19. Hottinger A.F., Pacheco P., Stupp R. Tumor treating fields: a novel treatment modality and its use in brain tumors. Rev. Neuro Oncol 2016; 18 (10): 1338-49. [PubMed]

20. Badaoui N., Meyronet D., Cartalat-Carel S., et al. Patterns of care and survival of glioblastoma patients: a comparative study between 2004 and 2008 in Lyon, France. Rev Neurol (Paris). 2014; 170 (3): 222-7. [PubMed]

21. McNamara M.G., Lwin Z., Jiang H., et al. Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era. J Neurooncol 2014; 117 (1): 153-60. [PubMed]

22. Gumusay O., Cetin B., Ozet A., et al. Factors predicting recurrence in patients with grade III glial tumors: Impact of adjuvant temozolomide on recurrence. J BUON 2014; 19 (4) 1035-40. [PubMed]

23. Tham C.K., See S.J., Tan S.H., et al. Combined temozolomide and radiation as an initial treatment for anaplastic glioma. Asia Pac J Clin Oncol 2013; 9 (3): 20-25. [PubMed]

24. Lashford L.S., Thiesse P., et al. Temo-zolomide in malignant gliomas of childhood: a United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 2002; 20 (24): 4684-91.

25. Cohen K.J., Pollack I.F., Zhou T., et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol 2011; 13 (3): 317-23. [PubMed]

26. De Sio L., Milano G.M., Castellano A., et al. Temozolomide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer 2006; 47 (1): 30-6. [PubMed]

27. Korshunov A., Ryzhova M., Hovestadt V., et al. Integrated analysis of pediatric glioblastoma reveals a subsets of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 2015. DOI 10/1007/s00401-015-1405-4 [PubMed]

28. Gururangan S., Fisher M.J., Allen J.C., et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol 2007; 9 (2): 161-16. [PubMed]

29. Khaw S.L., Coleman L.T., Downie P.A., et al. Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer 2007; 49 (6): 808-11. [PubMed]

30. Reyes-Botero G., Laigle-Donadey F., Mokhtari K., et al. Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults. J Neurooncol 2014; 120 (3): 581-6. [PubMed]

31. Baumert B.G., Hegi M.E., van den Bent M.J., von Deimling A. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.) Lancet Oncol 2016; 17 (11): 1521-32. [PubMed]

32. Koekkoek J.A., Dirven L., Heimans J.J., et al. Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide. J Neurol Neurosurg Psychiatry 2015; 86 (4): 366-73. [PubMed]

33. Gwak H.S., Yee G.T., Park C.K., et al. Temozolomide salvage chemotherapy for recurrent anaplastic oligodendroglioma and oligo-astrocytoma. J Korean Neurosurg Soc 2013; 54 (6): 489-95. [PubMed]

34. Nicholson H.S., Kretschmar C.S., Krailo M., et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer 2007; 110 (7): 1542-50. [PubMed]

35. Chamberlain M.C. Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study. J Neurooncol 2015; 122 (2): 329-38. [PubMed]

36. Osman M.A. Phase II trial of temozolomide and reirradiation using conformal 3D-radiotherapy in recurrent brain gliomas. Ann Transl Med 2014; 2 (5): 44. [PubMed]

37. Mark R., Gilbert J., et al. A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma. New Eng J Med 2014; 370 (8): 699-708.

38. Karajannis M.A., Zagzag D. Molecular Pathology of Nervous System Tumors. Biologycal Stratification and Targeted Therapies. Springer Science+Business Media, NY2015.

39. Broniscer A., Iacono L., Chintagumpala M., et al. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). Cancer 2005; 103 (1): 133-9. [PubMed]

40. Chiang K.L., Chang K.P., Lee Y.Y., et al. Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution. Childs Nerv Syst 2010; 26 (8): 1035-41. [PubMed]

41. Chassot A., Canale S., Varlet P., et al. Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol 2012; 106 (2): 399-407. [PubMed]

42. Rizzo D., Scalzone M., Ruggiero A., et al. Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise? J Chemother 2015; 27 (2): 106-10. [PubMed]

43. Щербенко О.И., Зорина Е.В., Зелинская Н.И., Пархоменко Р.А. Диффузно растущие опухоли ствола мозга как модель для оценки современных возможностей консервативного лечения неоперабельных глиом // Детская онкология, 2013; 3: 71-4.

44. Cohen K.J., Jabado N., Grill J. Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope? Neuro Oncol 2017; Mar 24. [PubMed]

45. Barker C.A., Chang M., Beal K., Chan T.A. Survival of patients treated with radiation therapy for anaplastic astrocytoma. Radiol Oncol 2014; 48 (4): 381-6. [PubMed]

46. Balañá C., Vaz M.A., Lopez D., et al. Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain. Clin Transl Oncol 2014; 16 (3): 273-9. [PubMed]

47. Barbagallo G.M., Paratore S., Caltabiano R., et al. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Neurosurg Focus 2014; 37 (6): P.E4. [PubMed]

48. Broniscer A., Chintagumpala M., Fouladi M., et al. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol 2006; 76 (3): 313-19. [PubMed]

49. Shonka N.A., Theeler B., Cahill D., et al. Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. J Neurooncol 2013; 113 (2): 305-11. [PubMed]

50. Peponi E., Tourkantonis I., Tasiou I., et al. Prognostic factors in glioblastoma patients managed with radiotherapy combined with temozolomide. J BUON 2014; 19 (3): 718-23. [PubMed]

51. Momota H., Narita Y., Miyakita Y., et al. Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. Pediatr Blood Cancer 2010; 55 (3): 577-9. [PubMed]

52. Messali A., Villacorta R., Hay J.W. A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments. Pharmacoeconomics 2014; 32 (12): 1201-12. [PubMed]

53. Raizer J.J., Fitzner K.A., Jacobs D.I., et al. Economics of Malignant Gliomas: A Critical Review. J Oncol Pract 2014; Dec 2. pii: JOP.2012.000560. [Epub ahead of print] [PubMed]


Для цитирования:


Щербенко О.И., Кумирова Э.В. К вопросу о возможностях персонализации применения химиотерапии опухолей мозга на примере темозоломида. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2017;16(2):84-90. https://doi.org/10.24287/1726-1708-2017-16-2-84-90

For citation:


Shcherbenko O.I., Kumirova E.V. To a question of personalisation opportunities of application of chemotherapy brain tumors on the example of a temozolomid. Pediatric Hematology/Oncology and Immunopathology. 2017;16(2):84-90. (In Russ.) https://doi.org/10.24287/1726-1708-2017-16-2-84-90

Просмотров: 153


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-1708 (Print)
ISSN 2414-9314 (Online)